Group 1 - The company announced that its subsidiary, Jiangxi Mayinglong Meikang Pharmaceutical Co., Ltd., received the drug registration certificate for Olopatadine Hydrochloride Eye Drops from the National Medical Products Administration [1][2] - The drug is classified as a prescription medication and is indicated for the treatment of allergic conjunctivitis-related eye itching [2] - The drug was first approved in the United States in 2004 and was imported and approved for sale in China in 2020 [2] Group 2 - As of 2023, the domestic market sales for Olopatadine Hydrochloride Eye Drops reached 255 million yuan [2] - The company has invested a total of 4.9224 million yuan in the research and development of this drug [2] - The approval of this drug is expected to enhance the company's ophthalmic product line [2]